People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cure Pharmaceutical Holding Corp. | — | Pharmaceuticals | Series B | $31.5M | $343.2M | 2018 |
| CURE PHARMACEUTICAL Corp | — | Pharmaceuticals | Series A | $9.9M | $10.0M | 2012 |
Edward Maliski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward Maliski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Davidson | 2 | 3 |
| Mark Udell | 2 | 2 |
| John Bell | 1 | 5 |
| Gene Salkind | 1 | 5 |
| Alex Katz | 1 | 5 |
| CHARLES BERMAN | 1 | 3 |
| Rob Davidson | 1 | 2 |
| Lauren Chung | 1 | 2 |
| JOSH HELD | 1 | 2 |
| Jessica Rousset | 1 | 1 |
| Ian Sephton | 1 | 1 |
| Vic Branstetter | 1 | 1 |
| Ed Maliski | 1 | 1 |
| Wayne Nasby | 1 | 1 |
| Jonathan Turman | 1 | 1 |
| Anya Goldin | 1 | 1 |
| Ruben King-Shaw | 1 | 1 |
| William Yuan | 1 | 1 |
| Nancy Duitch | 1 | 1 |
| Mike Redard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.